Prurigo nodularis is a rare, potentially debilitating, inflammatory skin disease characterized by disfiguring skin nodules often covering extensive areas of the body, and an intense and chronic itch
There are currently no approved therapeutic options
Nemolizumab is a first-in-class investigational monoclonal antibody that blocks the signaling of IL-31, a key neuroimmune cytokine involved in the pathogenesis of prurigo nodularis
This phase III trial met both primary endpoints, confirming nemolizumab monotherapy significantly improved skin lesions and pruritus (itch) in adult prurigo nodularis patients
The trial also met all key secondary endpoints, with a safety profile consistent with the phase II trial results